Clinical Trials Browser

Approved for marketing × INDUSTRY × Lymphoma, Mantle-Cell × Clear all

NCT01833039 2025-02-03

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Approved for marketing

Recurrence, Lymphoma, Mantle-Cell

NCT05172700 2024-12-18

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Approved for marketing

LymphoidOther hematologic neoplasm

Hematologic Diseases, Waldenstrom Macroglobulinemia, Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04162756 2021-10-14

ZUMA-18

Approved for marketing

Recurrence, Lymphoma, Mantle-Cell